Firms ally to develop drug for cancer, autoimmune disease

05/17/2013 | Genetic Engineering & Biotechnology News

RuiYi and Genor Biopharma agreed to co-develop the former's experimental monoclonal antibody drug RYI-008 against cancer and autoimmune diseases, particularly rheumatoid arthritis, in China. The deal follows RuiYi's announcement that it would use CMC Biologics' CHEF1 high-productivity expression plasmid to speed work on a cell line for RYI-008.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX